Investors have long asked the FDA to share its reasons for rejecting drugs, arguing that companies can use the agency’s silence on the matter to mislead the market.

Here are the key takeaways from the full Times Magazine story about the F.D.A.: The F.D.A.’s regulators have an enormous ...

Used for diagnosing gastroesophageal reflux, the devices may not attach or detach correctly, potentially causing serious ...

Jeneen Interlandi, a domestic correspondent for Opinion and a staff writer at the magazine, writes frequently about public health. For this article, she interviewed dozens of people who have worked ...

A new indication for omalizumab is prompting clinicians to adjust their approach to oral food challenges, but experts ...

Beyond staff cuts, the departures of some longtime investigators in recent months have left less experienced people tasked ...

Fatty liver disease affects more than 1 in 3 adults and often has no symptoms. A new drug developed with Tulane researchers ...

Unlike Drs. Adam Cifu and John Mandrola, I do not constantly boast of my "nuance" or claim to be a master of "clinical appraisal." They have so much to teach me.

The FDA has approved garadacimab-gxii for prophylactic use in patients aged 12 years and older with hereditary angioedema, ...

Canalevia-CA1, a canine-specific formulation of crofelemer, Jaguar's novel, oral plant-based drug sustainably harvested from the Croton lechleri tree, is available from multiple leading veterinary ...